Published in Medical Letter on the CDC and FDA, December 24th, 2006
Crucell will continue to capitalize on the rapidly growing vaccine market through increasing sales of marketed vaccines and developing and introducing new vaccines. The company is leveraging its PER.C6 technology in the rapidly growing protein market. On November 8, Crucell and DSM Biologics announced the opening of the Percivia PER.C6 Development Center in Cambridge, Massachusetts. PERCIVIA will continue to further...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.